Previous close | 79.81 |
Open | 81.00 |
Bid | 78.90 x N/A |
Ask | 82.94 x N/A |
Day's range | 80.80 - 81.92 |
52-week range | 72.84 - 89.28 |
Volume | |
Avg. volume | 1,285,663 |
Market cap | 181.256B |
Beta (5Y monthly) | 0.48 |
PE ratio (TTM) | 7.81 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.10 (3.90%) |
Ex-dividend date | 08 Mar 2022 |
1y target est | N/A |
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.
Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.